糖尿病视网膜病变的口服疗法:解决未满足的需求还是遥远的前景?
Theo Empeslidis1, Georgios D Panos2,3, Konstantinos Balaskas4
1Vantage Biosciences, UK.
The Journal of international medical research
|December 22, 2025
概括
糖尿病视网膜病变的全身疗法显示出有前途,而纤维酸证明了一致的益处. 需要进一步的研究来优化试验设计,并探索这种危及视力的并发症的新型口服治疗方法.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病视网膜病变 (DR) 是导致视力丧失的主要原因.
- 系统疗法对DR的局部治疗有潜在的优势.
- 了解口腔DR疗法的机制和证据至关重要.
研究的目的:
- 审查对DR系统性口服治疗的生物学理由,临床证据和实践方面.
- 分析针对DR病变发生的不同途径的各种类型的口服药物.
- 讨论这些疗法的试验设计和临床整合.
主要方法:
- 对DR的全身口服疗法进行叙述性审查.
- 检查视网膜神经血管单元内的机械路径.
- 对特定药物类别 (PPAR-α激动剂,PKC-β抑制剂等) 的临床证据的评估. ) 的情况.
主要成果:
- 费诺纤维酸 (PPAR-α激动剂) 显示出一致的预防恶化的信号.
- 其他药物如ruboxistaurin和APX3330已经显示混合或特定子集的有效性.
- 挑战包括终点异质性和大多数药物的有限的第三阶段数据.
结论:
- 针对DR的全身口服疗法具有不断发展的证据基础.
- 需要优化试验设计,专注于预防和更长的持续时间.
- 费诺纤维酸是研究最多的药物,但对于其他口服疗法仍然存在差距.
关键词:
在APX333030中使用.糖尿病视网膜病变 - 糖尿病视网膜病变这是一种ROCK抑制剂.这是一种VAP-1/AOC3抑制剂.临床试验的终点临床试验的终点疾病的进展 疾病的进展芬诺纤维酸盐的使用方法口服治疗是一种口服疗法.视网膜神经血管单位 视网膜神经血管单位卢博克斯斯塔乌林的情况更多相关视频
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
9.5K
12:56Methodology for Biomimetic Chemical Neuromodulation of Rat Retinas with the Neurotransmitter Glutamate In Vitro
Published on: December 19, 2017
8.1K
相关概念视频
Diabetes: Management and Pharmacotherapy
844
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
844
Open Angle Glaucoma: Treatment
920
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
920
Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
